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ABSTRACT
This grant utilizes complimentary approaches to improve the early detection of lung cancer. Our goal is to explore whether detection of DNA methylation changes and enhanced CT evaluations will add to the specificity of lung cancer detection. Based on our previous development of an improved panel of genes hypermethylated in lung cancer, with extraordinarily high specificity and sensitivity, we combined the improved methods of MOB with highly sensitive methylation specific PCR assays suitable for biologic fluid testing (sputum and serum) and completed the study of a cohort of cancer positive and negative samples. In combination with these molecular detection approaches, we have examined the alterations in air space for improving detection of lung cancer and find that variability of air spaces is associated with the presence of lung cancer. We have during the period of this grant developed a highly sensitive and specific method for early detection of lung cancer.
INTRODUCTION:
This grant utilizes complimentary approaches to improve the early detection of lung cancer. Our goal is to explore whether detection of DNA methylation changes and enhanced CT evaluations will add to the specificity of lung cancer detection. This was defined in our aims. Specific Aim 1: To improve the clinical utility and effectiveness of a nested, gel based DNA methylation assay for sputum and plasma by increasing its sensitivity and specificity through nanotechnology. Hypothesis: Detection of DNA methylation from individuals with cancer can be used to determine lung cancer risk and can be enhanced through discovery of optimal hypermethylated genes and implementation of enhanced detection technologies. Specific Aim 2: To use an in vitro molecular testing of sputum and serum with DNA methylation rather than simple demographics alone to select the highest risk smokers for an expensive screening modality such as CT scanning. Hypothesis: DNA methylation testing is more specific in selecting those at the highest risk for lung cancer than clinical demographics alone. Specific Aim 3: To optimize low dose chest CT screening for lung cancer. Hypothesis: Valuable information on the chest CT scan, based on the severity, distribution, and pattern of low attenuation areas ("emphysema"), may be crucial to increasing our insights and effectiveness of determining lung cancer risk, the frequency of follow up scans, reducing false positives, and controlling costs compared to an annual chest CT screening for the sole use to detect lung cancer tumors after they occur.
KEYWORDS:
Lung Cancer Screening, CT Screening, DNA Methylation Detection, Emphysema Score, Lung Airspace Variability Score.
OVERALL PROJECT SUMMARY:
During the first two years of this proposal, we had largely accomplished the goals of building an improved method for methylation detection which comprise specific aim 1. We made significant progress on the two sub-aims of this proposal in implementing the developments from last year. Last year's progress included A) Developing optimal hypermethylated gene panels for detection of tumor DNA from lung cancer and B) Optimize nanotechnology based detection of DNA methylation for increased sensitivity and specificity. The first efforts were initially focused on the development of an optimal gene panel for detection of lung cancer. After completion of these studies, we published the results earlier (1) with a summary provided here. Hypermethylation of CpG islands is a common and important alteration in the transition from normal to transformed cells. Following previously validated methods for the discovery of cancer-specific hypermethylation changes from NSCLC cell lines, we identified >300 candidate genes. Using the Cancer Genome Atlas (TCGA) and employing extensive filtering to refine our candidate genes for the greatest ability to distinguish tumor from normal, we had initially defined a three-gene panel, CDO1, HOXA9, and TAC1, which we subsequently validate in two independent cohorts of primary NSCLC samples. This 3-gene panel is 100% specific, showing no methylation in 75 TCGA and 7 primary samples and is 83-99% sensitive for NSCLC (shown in last year's progress report). This panel has been further expanded through the identification of additional genes with extremely high methylation frequencies in lung cancer. This panel now includes three additional genes, HOXA7, SOX17 and ZFP42, for which real-time MSP analyses assays were also developed to complement the previous 3 gene panel to provide redundant tumor coverage to optimize detection. Our subsequent development of this panel expanded into 6 genes with good sensitivity and specificity, with results shown for 5 genes. Figure 1 . Methylation of CDO1, HOXA9, SOX17, ZPF42 and TAC1 is Highly Sensitive for NSCLC Detection, in stage I lung cancer samples. Highly prevalent methylation sites were chosen from data generated within the TCGA studies. All normal lung tissue lack DNA methylation, but the majority of lung tumors have methylation of individual loci, and overall, nearly all tumors have methylation of at least one loci (adapted from Wrangle (1) . These new assays were confirmed to specifically detect abnormal methylation using normal lymphocytes and in vitro methylated bisulfite converted DNA. We found high specificity to methylation in bisulfite converted DNA and no amplification in unconverted and no template controls. These new assays were deployed in specific aim 2 with good results. Aim 2: The use of methylated tumor-specific circulating DNA has shown great promise as a potential cancer biomarker. Nonetheless, the relative scarcity of tumor-specific circulating DNA presents a challenge for traditional DNA extraction and processing techniques. We completed a study of improvements in DNA processing, with a single tube extraction and processing technique dubbed "methylation on beads" that allows for DNA extraction and bisulfite conversion for up to 2 ml of plasma or serum (Outline of approach shown in figure 2 ) (2). In comparison to traditional techniques such as phenol chloroform and alcohol extraction, methylation on beads yields a 1.5 to 5-fold improvement in extraction efficiency. The greatest enhancement in extraction efficiency is seen with small amounts of DNA, precisely matching the need for improved extraction in low DNA content samples such as plasma and serum. A summary of the final results using this approach is provided in figure 3 . Figure 2 . Overview of the Methylationon-Beads (MOB) Process. Circulating DNA from up to 2 ml of plasma is extracted and purified via SSBs. The purified DNA is then subject to bisulfite conversion and analyzed via methylation specific PCR (MSP). The entire sample preparation process can be performed in a single tube and consists of an iterative process of adding reagents, magnetic decantation, and removal of supernatant. Figure 3 Having developed an optimal panel and improved upon methods for processing the DNA as planned, we have applied these techniques to the plasma and serum of patients with CT detected lung cancer and those with non-cancerous nodules, and have completed the writing of a manuscript containing these results. The abstract of that manuscript is as follows (full manuscript in appendix): Purpose: To improve the diagnostic accuracy of lung cancer screening using ultrasensitive methods detecting gene promoter methylation in sputum and plasma using Methylation-On-Beads (MOB) with a lung cancer specific gene panel. Patients and Methods: This is a case-control study of subjects with nodules suspicious for lung cancer on CT imaging in which plasma and sputum were obtained pre-operatively. Cases (n=150) had pathological confirmation of node negative (stage IA, IB and IIA) non-small cell lung cancer while controls (n=60) had non-cancer diagnoses. We detected promoter methylation using quantitative methylation specific real-time PCR with MOB for cancer-specific genes (CDO1, TAC1, HOXA7, HOXA9, SOX17 and ZFP42) identified from The Cancer Genome Atlas (TCGA). Results: DNA methylation was detected in plasma and sputum more frequently in people with cancer compared to controls (p<0.001) for 5 of 6 genes examined. Individual gene detection The sensitivity and specificity for lung cancer diagnosis using individual genes from sputum ranged from 63-93% and 42-92% respectively and from plasma from 33-91% and 52-94%. A three-gene combination including the best individual genes has sensitivity and specificity of 93% and 79% using sputum and 91% and 64% using plasma. Area under the Receiver Operating Curve for this panel was 0.89 95% CI (0.80-0.98) in sputum and 0.77 95% CI (0.68-0.86) in plasma. Independent, blinded random forest prediction models combining gene methylation with age, pack-year, COPD status and FVC values correctly predicted lung cancer in 91% of subjects using sputum samples and 85% of subjects using blood samples. Conclusions: High diagnostic accuracy for early stage lung cancer can be obtained using methylated promoter detection in sputum or plasma. Methylation was readily detected for these loci in the majority of cancer patients, but not in most control patients. Actual quantitation of the methylation was carried out with the following DNA Methylation analysis:
The genomic sequence for the genes and 1000 bases upstream was obtained from the UCSC genomic browser website. The primers and hybridization probes for methylation analysis were designed based on this sequence by using Primer3 (v.0. The results of the methylation analyses for these six genes in the 210 patients are shown, with tumor methylation, sputum and plasma results. and sputum from patients with Lung cancer and non-cancer controls, plotted on log scale. Each dot represents the calculated level of methylation using the formula above from triplicates. Note the nearly universal detection of methylation in all tumor tissues, and at higher quantitative levels than seen in biologic fluids (as expected given the relative amounts of tumor DNA in tissue samples compared to plasma or sputum). Plasma and sputum samples vary in quantity of methylation from equal to that in tumor to very low level detection (10-5-10-6)_This low level detection was not possible without the integrated methods described for this proposal
With these results, we calculated the analytic accuracy of methylation detection. 
Independent Prediction Accuracy
Performance: While the above analysis looked at individual gene methylation in cases and controls to detect cancer, independent blinded random forest prediction models analyzed all these biomarkers in combination with clinical risk factors. Risk factors included in the first two random forest prediction models were methylation Ct values from all six genes, age, pack-year, COPD status and FVC values. The methylation Ct values were not included in the last prediction model. The randomly selected training dataset has 140 subjects with 99 (70.7%) cancers and 41 (29.3%) controls. The independent test set has 70 subjects with 51 (72.9%) cancers and 19 (27.1%) controls. In the variable of importance output of the first two random forest prediction models, methylation Ct values were ranked as more important variables than demographic and clinical variables ( Figure 6 ). Table 3 summarizes the prediction accuracies of these three models when they were applied to the independent test set patients. With sputum samples, the random forest model correctly predicted lung cancer in 91% of subjects in the test subset. The corresponding AUC was 0.85 95% CI (0.59-1.0) . The sensitivity and specificity of the prediction in the testing subset from the ROC curve were 0.93 and 0.86, respectively. Using plasma samples, the random forest model correctly predicted lung cancer in 85% of subjects in the testing subset. The corresponding AUC was 0.89 95% CI (0.79-0.99). The sensitivity and specificity of the prediction in the testing subset from the ROC curve were 0.93 and 0.67, respectively. Using clinical and demographic risk factors alone, the accuracies were lower than the first two models with a diagnostic accuracy of 68%, AUC of 0.64, PPV of 75% and a NPV of 38% (Table 3 ). . The x-axis is the mean decrease in the Gini co-efficient that results when that variable is included in the model. The Gini coefficient is a measure of inequality among the trees in the random forest, and in this case represents the performance of the random forest model with and without a variable included. Those variables that have the highest decrease in the Gini coefficient were most likely to create consensus among the individual decision trees used in the model (or reduce inequality) when included in the model. These variables are therefore most predictive of the outcome of the model overall. Those variables with a small decrease in the mean Gini coefficient are relatively less important to the prediction made by the random forest model. In the final period of our funding, the PI (Dr. Herman) moved to the University of Pittsburgh and has begun to implement this approach in samples from the Lung Cancer Pittsburgh Screening study (PLuSS) and the Pittsburgh Lung Cancer SPORE. This will form a validation cohort and be used to further improve this already promising approach.
For specific aim 3, to date we were able to identify 210 subjects in the SPORE database that had CT scans performed prior to surgery which were adequate for analysis. We have completed measurement of the extent of computed tomography (CT) in these subjects. Of the group, 168 of the subjects had cancer, and 42 did not. The software can divide the lung into upper, middle, and lower fields on the right and the left for a total of six lung areas. For the subjects, clearly abnormal areas were eliminated from further analysis. For the Ca+ subjects, the final usable number of lung fields were right upper=106, right middle=111, right lower=108, left upper=118, left middle=118, and left lower=116. For the Ca-subjects, we have 103 for each lung field. The emphysema score was based on the number of voxels with Hounsfield units (HUs) less than -910. The percent emphysema of the lungs ranged from 0.19 to 56% among all the subjects with a mean score of 28.815% (meanSD). The subjects with and without cancer had a similar amount of emphysema (2915 and 2714 respectively (p=0.42) . This suggests that simple screening for emphysema would not allow for detection of lung cancer. We continued the study of CT images, examining lung heterogeneity by comparing the ratio of the upper to the lower lung in regards to the mean, standard deviation, <-950 HU, and 15 th percentile of the CT scans comparing cancer and non-cancer. The software divides the scans into right and left, allowing the examination of these 4 variables for each side separately. The only variable that was significant, and was significant on both the right (p=0.0091) and left (p=0.0454) was the 15 th percentile. The mean HU value for the right side was close (p=0.0785). We next combined the right and left sides to have a single overall measure. (Figure 7 ) The average (rightleft) upper to lower ratios for the mean CT score, standard deviation of the mean, <-950 HU, and 15 th percentile of the CT scans comparing the cancer to the non-cancer subjects. Again the average (rightleft) upper to lower ratio for the 15 th percentile was significant (p=0.0014). In addition, the average (rightleft) upper to lower ratio for the mean CT density was also significant (p=0.04) (Figure 8 ). Neither the standard deviation (p=0.43) or the <-950HU (p=0.26) measurements were significant. These findings suggest that the upper to lower ratio of the mean intensity may be an independent predictor of lung cancer. These findings suggest that the upper to lower ratio of the 15 th percentile of lung intensity may also be an independent predictor of lung cancer.
Considering these two significant variables into a single Generalized Linear Model (GLM) as independent variables and cancer as the outcome variable, i In this model, only the 15 th percentile was significant (p=0.0055). 
Generalized Linear Model Fit
KEY RESEARCH ACCOMPLISHMENTS:
 Completion of sputum and plasma analysis from 210 subjects in a case control study of 150 with early stage lung cancer and 60 non cancer controls.  Demonstration of specific and sensitive detection of cancer specific DNA methylation as an early detection biomarker.  Transition of Studies to the University of Pittsburgh.  Studies of emphysema and variability scores completed 127 subjects with a diagnosis of lung cancer and 180 subjects without a diagnosis of lung cancer.
CONCLUSION:
In summary, based on our previous development of an improved panel of genes hypermethylated in lung cancer, with extraordinarily high specificity and sensitivity, we combined the improved methods of MOB with highly sensitive methylation specific PCR assays suitable for biologic fluid testing (sputum and serum) and completed the study of a cohort of cancer positive and negative samples. In combination with these molecular detection approaches, we have examined the alterations in air space for improving detection of lung cancer and find that variability of air spaces is associated with the presence of lung cancer. We have during the period of this grant developed a highly sensitive and specific method for early detection of lung cancer. To improve the diagnostic accuracy of lung cancer screening using ultrasensitive methods detecting 5 gene promoter methylation in sputum and plasma using Methylation-On-Beads (MOB) with a lung 6 cancer specific gene panel. 7
PUBLICATIONS, ABSTRACTS, AND PRESENTATIONS:
10. REFERENCES: List all references pertinent to the report using a standard journal format (i.e. format used in Science, Military Medicine, etc.) stage I lung cancer. New England Journal of Medicine. 2008;358(11):1118-28. doi: papers2://publication/doi/10.1056/NEJMoa0706550. 19
Patients and Methods: 8
This is a case-control study of subjects with nodules suspicious for lung cancer on CT imaging in 9 which plasma and sputum were obtained pre-operatively. Cases (n=150) had pathological confirmation 10 of node negative (stage IA, IB and IIA) non-small cell lung cancer while controls (n=60) had non-11 cancer diagnoses. We detected promoter methylation using quantitative methylation specific real-time 12
PCR with MOB for cancer-specific genes (CDO1, TAC1, HOXA7, HOXA9, SOX17 and ZFP42) 13 identified from The Cancer Genome Atlas (TCGA). 14
Results: 15
DNA methylation was detected in plasma and sputum more frequently in people with cancer compared 16 to controls (p<0.001) for 5 of 6 genes examined. Individual gene detection The sensitivity and 17 specificity for lung cancer diagnosis using individual genes from sputum ranged from 63-93% and 42-18 92% respectively and from plasma from 33-91% and 52-94%. A three-gene combination including the 19 best individual genes has sensitivity and specificity of 93% and 79% using sputum and 91% and 64% 20 using plasma. Area under the Receiver Operating Curve for this panel was 0.89 95% CI (0.80-0.98) in 21 sputum and 0.77 95% CI (0.68-0.86) in plasma. Independent, blinded random forest prediction models 22 combining gene methylation with age, pack-year, COPD status and FVC values correctly predicted 23 lung cancer in 91% of subjects using sputum samples and 85% of subjects using blood samples. 24
Conclusions: 25
High diagnostic accuracy for early stage lung cancer can be obtained using methylated promoter 26 detection in sputum or plasma. 
29) 52
In addition, previous studies have selected genes for DNA methylation detection primarily 53 chosen from a candidate approach, which are methylated in only a fraction of tumors. The Cancer 54
Genome Atlas (TCGA) (30) provides the opportunity to discover cancer specific methylation changes 55 optimal for detection. We had . reported the identification of six genes (CDO1, HOXA7, HOXA9 , 56 TAC1, SOX17, and ZFP42) with a high prevalence of methylation changes present in lung squamous 57 and adenocarcinoma, but not normal lung tissue.(1) These were developed into sensitive assays using 58 MOB and real-time Methylation-Specific PCR (qMSP) to determine the diagnostic accuracy in sputum 59 and plasma for lung cancer detection in a case-control study. 60 Real-Time PCR system was used (Applied Bio Systems, examples shown in Supplemental Figure 1) . 108 With the extremely low levels of DNA methylation in plasma and sputum, replicates for some 109 samples produced no detectable methylation as expected. To incorporate this information into the final 110 quantification of methylation, we calculated the 2 -ΔCT for each methylation detection replicate 111 comparing it to the mean Ct for β-Actin (ACTB). For replicates which were not detected (ND), a CT 112 of 100 was used, creating a near zero value for 2 -ΔCT . Data was analyzed using two approaches. The first approach is the ROC analysis using the 2 -
Patients and Methods
61
Study Population
121
ΔCT values for individual genes to determine the performance of each individual marker. The three best 122 performing genes were selected for diagnostic accuracy for lung cancer detection, based on receiver 123 operator classification (ROC) curves and were used for combined detection. Sensitivity and specificity 124 values were obtained from the optimum cutoff thresholds from ROC curves (R statistic software, 125 version 3.0.2, Vienna, Austria). (37) The area under the curve was reported with 95% CIs. 126
The second approach utilized independent blinded random forest prediction models, a non-127 parametric machine learning method, to evaluate the utility of the six-gene panel and clinical data in 128 early lung cancer detection. The analysis combined gene methylation with clinical risk factors: nodule 129 size, age, pack-year, COPD status and FVC values (Figure 4) . Two-thirds of subjects were randomly 130 selected as a training set and the remainder formed the test set. A statistician (PH), blinded to the true 131 diagnosis codes of the test set patients, used the training set to build three random forest prediction 132 models: the first one used all six-gene sputum biomarkers plus clinical and demographic risk factors, 133 the second used the six-gene plasma biomarkers and clinical, and a third used only clinical and 134 demographic risk factors without any methylation biomarkers. These three models were ysed to predict 135 cancer status from the independent test set. Prediction accuracy was reported as the proportion of test 136 set subjects correctly predicted by the random forest classification models, allowing calculation of 137 sensitivity, specificity, and ROC analysis. 138
Results
139
Characteristics of the Patients
140
Two hundred and ten patients fulfilled inclusion criteria, , with 150 node negative early stage 141 lung cancer subjects and 60 controls with non-cancerous lung lesions ( Table 1) 
Detection of DNA Methylation
148
We measured DNA methylation for these genes in tumor tissue, confirming our previous study 149 suggesting these genes were methylated in the majority of lung tumors (Figure 1 ). Methylation in 150 sputum was detected more frequently in all 6 genes in cancer patients compared to controls ( Figure  151 1[J4]), which for some patients was quantitatively similar to lung tumor tissues, but in some cases was 152 at levels previously below conventional methods of detection. For 5 of the 6 genes, (CDO1, TAC1, 153 HOXA7, SOX17 and ZFP42) this was statistically significant (p < 0.001). Methylation of all 6 genes 154 was detected more frequently in plasma in cases compared to controls (p < 0.001). The worst 155 performing gene was HOXA9 in plasma, which showed a lack of specificity as was also seen in the 156 sputum. We determined the sensitivity and specificity in this cohort using the presence or absence of 157 detectable methylation without considering the quantitation of methylation. This resulted in good 158 sensitivity and specificities (Table 2a) (Figure 2A) , with 167 sensitivities and specificities for TAC1 84% and 79%; SOX17 84% and 88%; HOXA7 63% and 92% 168 respectively. The positive and negative predictive values for these three genes were: TAC1 94% and 169 57%; SOX17 96% and 59%; HOXA7 97% and 40% respectively. 170
In plasma, the genes with the largest areas under the curve (AUC) were: CDO1 AUC: 0.68 171 95% CI (0.58-0.77), TAC1 AUC: 0.78 (0.70-0.86) and SOX17 AUC: 0.78 95% CI (0.70-0.86) (Figure  172 2B), with corresponding sensitivities and specificities of: CDO1 65% and 74%; TAC1 76% and 78%; 173 SOX17 71% and 86% respectively. The positive and negative predictive values for these genes were: 174 CDO1 86% and 46%; TAC1 90% and 57%; SOX17 93% and 54% respectively. 175
The sensitivity and specificity derived from the optimum cutoff point obtained from the ROC 176 curve in the combination of the three best performing markers (TAC1, SOX17 and HOXA7) in sputum 177 was 93% and 79%, respectively with a corresponding ROC AUC of 0.89 95% CI (0.80-0.98) (Figure  178 2C). In plasma, the combination of CDO1, TAC1 and SOX17 showed a sensitivity, specificity and 179 AUC of 91%, 64% and 0.77, 95% CI (0.68-0.86). respectively ( Figure 2D) . 180
Smokers subset analysis
181
Since CT screening for lung cancer is currently recommended for current and ex-smokers, we 182 explored the diagnostic accuracy when only smokers were considered (n=155; 114 with cancer and 41 183 without cancer) (Supplemental Tables for Only Smokers S2) . The results in only smokers were 184 similar to the entire study population for the prevalence of methylated patients, sensitivity, specificity 185 and AUC (Supplemental Table S3 ). AUC in smokers only was 0.89 95% CI (0.79-0.99) for the 186 combination of the methylation status of the best three genes from sputum and AUC 0.85 95% CI 187 (0.76-0.94) from the best three genes from plasma (Supplemental Table S4 & S5) . 188 test set has 70 subjects with 51 (72.9%) cancers and 19 (27.1%) controls. In the variable of importance 196 output of the first two random forest prediction models, methylation Ct values were ranked as more 197 important variables than demographic and clinical variables (Figure 3 and 4) . Table 3 MOB. This assay has several characteristics which make it clinically useful (i) it has a sensitivity and 212 specificity in sputum and plasma which exceeds the diagnostic accuracy required by most clinical 213 standards (12, 38) (ii) it can be performed with minute quantities of DNA from sputum or plasma (iii) it 214 can be used to distinguish malignant versus benign CT detected nodules, addressing the current 215 problem of high false positive CT findings in lung cancer screening. This discrimination is associated 216 with risk of lung cancer independent of age, pack-year and nodule size, and is can detect early stage 217 lung cancer in smokers. Finally, as a PCR-based assay, it is simple and relatively inexpensive. 218
Independent Prediction Accuracy Performance
Previous studies have sought to improve lung cancer risk assessment by the use of molecular 219 biomarkers obtained from blood and sputum. (17, 19, 20, 32, 33, 39, 40) However none of these tests 220 have been used clinically because their achieved sensitivities and specificities were usually not high 221 enough for clinical decision-making. (17, 19, 20, 32, 33, (39) (40) (41) With improvements in DNA extraction 222 methods and processing for methylation detection, along with the use of highly prevalent cancer 223 specific methylation targets, we have overcome these obstacles. 224
In this study, detection of methylation in sputum samples was slightly better than the detection 225 of these same genes in plasma. The access of early cancers to the airways may be one explanation for 226 this difference. Indeed, changes in the airways form the basis for the AEGIS Study, which reported an 227 improved diagnostic yield of bronchoscopy using gene-expression classifiers from epithelial cells 228 collected during bronchoscopy.
(41) The AUC, sensitivities and specificities reported in the AEGIS 229 Study were lower than the ones in the present study. 230
In our model where methylation markers from blood were considered simultaneously with age 231 and number of pack-years, we observed a predictive accuracy close to that of sputum. This suggests 232 that blood could substitute for sputum in lung cancer detection in those cases where sputum cannot be 233
obtained. 234
According to the NLST, the chances of having lung cancer with a positive CT screening are 235 less than 5%.(6, 7) This is because lung cancer with CT screening in the NLST study yielded a 71% 236 sensitivity but a 63% specificity with a 96.4% false positive rate.(6, 7) Our current findings indicate 237 that methylation detection using a few genes from blood and sputum could potentially reduce false 238 positive screening. Although our study included patients who would not meet current lung cancer 239 screening guidelines, we observed similar detection rates when only smokers were analyzed. 240
Replication and external validation of our findings in a large, prospective, multicenter case control trial 241 are essential before this approach can be adopted. 242
Conclusion
243
This study shows that it is possible to obtain high sensitivity and specificity detection of early 244
stage NSCLC using a panel of methylated promoter genes in plasma and sputum, and that the 245 methylation level of these genes is associated with a high lung cancer risk independent of age, pack-246 year and nodule size. These epigenetic biomarkers could be used as an adjunct to CT screening to 247 identify patients at high risk for lung cancer, reducing false positive results, unnecessary tests, as well 248 as improving the diagnosis of lung cancer at an earlier stage. 249 ROC curves assessing the accuracy of the predictions for lung cancer performed on the testing subset by using as predictors the ΔC t values for all six genes, age, pack-year, COPD status and FVC values.
The left plot is obtained using sputum samples, the middle one using blood samples and the right one the ROC curve for the clinical predictors alone. 
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